Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (14026)	8/27/1999 11:10:00 AM
From: CrayUSA	Read Replies (1) \| Respond to of 52051

HIV---just took a bite. Got a Strong buy recommendation from Gateway capital (never heard of them) of 105 dollars in a year. It is trading at 3 1/2. Biotek company. Cray

To: Stock Watcher who wrote (14026)	8/27/1999 11:13:00 AM
From: RCJIII	Respond to of 52051

Poke plays are coming back, SYCD just put out some great news- (BSNS WIRE) SyCoNet.com Retail Division Sales Soar At Comicon Convention SyCoNet.com Retail Division Sales Soar At Comicon Convention; SyCoNet.com Becomes Exclusive U.S. Distributor of Entire Anime Product Line Business/Technology Editors MANASSAS, Va.--(BUSINESS WIRE)--August 27, 1999--SyCoNet.com, Inc. (OTC BB:SYCD), the leading U.S. distributor of Anime (Japanese animated) videos and DVDs, today announced that sales of its retail division Alternative Video Warehouse increased significantly at the recent San Diego Comicon convention, and established the Company as the sole distributor of all Anime product offerings. SyCoNet.com's retail division Alternative Video Warehouse witnessed phenomenal sales while attending one of the largest comic book conventions this year Comicon in San Diego, CA from August 12th through August 15th. The Company's retail sales increased 25% over last year's participation. Alternative Video Warehouse also gained 22 key agreements with retailers to merchandise its Anime products. The new specialty retailers include Lonestar, one of the nation's leading comic chains, currently operating eight stores in Texas, as well as Camelot Comics of Argentina. Chief executive officer Sy Picon stated, "We are thrilled with the response our retail division received at the Comicon convention. Alternative Video Warehouse continues to draw impressive sales through participation in conventions nationwide. Retaining over 20 new retail outlets should greatly impact the Company's top line growth." SyCoNet.com also announced it is the only United States distributor to specialize in the entire Anime product line. The Company keeps over 25,000 Anime videotapes from every available manufacturer in its inventory, making SyCoNet.com the largest Anime video distributor. Sy Picon commented, "Our entirely comprehensive Anime product offering yields a significant advantage over other suppliers and delivers superior convenience to the consumer, which increases our orders and lowers customer turnover." Alternative Video Warehouse will participate in roughly 25 conventions nationwide during 1999. For more information on purchasing the Internet's lowest priced Anime videos, see www.altvidwar.com. SyCoNet.com, Inc., formerly SyCo Distribution, Inc., distributes Anime Japanese animated movies, including the enormously popular Pokemon(r) video series, live action cult films, multimedia games and software, DVDs, CDs, toys, apparel, and related merchandise to over 1,000 wholesale and retail accounts nationwide through two high-traffic websites, a catalog, and direct sales campaigns. Also see www.otcfn.com/sycd, www.altvidwar.com, and www.sycodistribution.com Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. --30--kc/bos* CONTACT: SyCoNet.com OTC Financial Network Sy Picon Geoffrey Eiten 703-366-3900 877-663-0266/781-444-6100 ext. 13 admin@altvidwar.com geiten@otcfn.com KEYWORD: VIRGINIA INDUSTRY KEYWORD: COMED COMPUTERS/ELECTRONICS INTERACTIVE/MULTIMEDIA/INTERNET Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *

To: Stock Watcher who wrote (14026)	8/27/1999 11:56:00 AM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 52051

WASP is looking great again SW. It's at .86 x .90 and moving well. The previous 52 week high is 2 1/2: WASP - OTC BB Float: 5.1 Million shares Outstanding: 17 Million shares Wasatch Pharmaceutical has been in business since 1986. Until recently they have been largely a research and development company. Earlier this year in a series of press releases the company discussed the outstanding results of their research. As a result the stock ran to $2 1/2 per share. I read those press releases but I was skeptical... I kept scratching my head and wondering... How can they make these claims? I found out when I received my investor package and then discussed the treatment results with CEO Gary Heesch. With several thousand patients having been treated, Wasatch has announced a success rate of 95% with virtually no side effects. Success is interpreted as total or near total eradication of both cystic acne and the less serious grades of acne. This product is used topically, and is far superior to anything now being used by prescription or in the over-the-counter market. fast.quote.com. For all types of Eczema treated in this study, Wasatch realized an 85% success rate. Success is interpreted as total or near total eradication of this pervasive skin condition. biz.yahoo.com In the case of Psoriasis, we have treated approximately 20 patients with a success rate of 45%. The most important aspect of this study is the total or almost total eradication of the disease for those who responded. With these results, Wasatch is confident that within two years of continued research, this skin disorder will respond to treatments involving an improved therapeutic approach. biz.yahoo.com Cold Sores are now treated successfully with existing products. Wasatch's entry into this market will provide a new dimension for the treatment of this skin problem. With a success rate exceeding 95%, our most important achievement is the time taken to eradicate the cold sore. For the most part, existing therapies take 2-10 days to eliminate the sores. In studies conducted by Wasatch, the time is reduced to 2-3 days, whether on the skin surface or in the mouth. biz.yahoo.com The medications they use are all FDA approved antibiotics and others beneficial medicaments. However they have never been used in the proper combination to achieve this high degree of success until now. The company has filed for FDA approval for 7 different OTC applications earlier this month. While approval is still a ways off the company is already preparing to sell certain products that will not require FDA approval: biz.yahoo.com They currently have two clinics in Utah. Diseases that they have cures for in skin care: Acne, Psoriasis and Eczema. The management team is focused on research and development of other products. Over 2000 clinical studies have been performed and published. Success rate is far above any others in the marketplace with less side effects. Wasatch even has a skin rejuvenation product that actually rebuilds skin cells. The market for the above is 10 billion a year. fast.quote.com. Company intends on opening 300-400 clinics over the next 3-5 years. The two clinics which are already open will be profitable by November of 1999. The company expects the real revenues to kick in by the first quarter of 2000. The company is doing everything possible to build a strong management team within the next 60 to 90 days. As such they plan to hire a new CEO who worked for over two decades at Johnson and Johnson in a high level management position in their skin care division: biz.yahoo.com The only hold up has been funding. I expect the initial funding could be announced within the next couple of weeks. Everything should fall into place soon and the company should begin to move full speed ahead into it's expansion phase. Applications are already be processed on Blue Cross and Blue Shield coverage.All of the clinics will operate under the name of American Institute of Skin Care. The company even has a tremendous opportunity in the veterinary medicine area as well. Projected revenues for 3-5 years down the road exceed over 500 million a year. All the due diligence which I have provided here should be followed up by due diligence of your own. I invite you to call Gary Heesch of Wasatch Pharmaceuticals before investing your hard earned dollars. Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709